Postmarketing Trials, Not Discount Cards, Promote Drug Value, Harvard's Porter Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies find themselves playing defense in debates on cost issues like reimportation because they have failed to demonstrate the value of their products, the Harvard Business School professor says. Merck's April announcement of a drug discount card program for the uninsured does not help promote value, Porter adds.
You may also be interested in...
Merck's Discount Drug Program For Uninsured Will Not Include Income Limits
The program will allow uninsured patients, regardless of age or income level, to receive Merck drugs at discounts of 15%-40% at retail pharmacies. The program goes up against Together Rx Access, which is sponsored by a 10-member consortium of pharma companies.
Four Senate Bills Signal Start Of 2005 Rx Importation Debate
Two partisan bills will compete with the reintroduction of the Dorgan/Snowe bill and the Pharmaceutical Market Access Act passed by the House in 2003. The Senate Health Committee plans to hold a hearing on the Dorgan/Snowe bill within 90 days.
Together Rx Access Card Program Provides Discounts To Non-Seniors
Coalition includes seven members of Together Rx program, plus Pfizer, Takeda and TAP. Together Rx Access will provide drug discounts to low-income, uninsured individuals under age 65; Merck is developing its own card for all uninsured Americans.